United Therapeutics Corp. (UTC) and Liquidia Technologies Inc. have been battling for close to a decade over their respective inhaled formulations ...

At the forefront of this movement is Andre Dowdell Jr., CEO and founder of Liquida Capital, an American-based financial services firm reshaping how businesses access and use capital ...

Yutrepia's maker, Liquidia, has scheduled a first commercial shipment of the PH therapy to be available at specialty ...

This decision came after the full FDA approval of YUTREPIA inhalation powder for adults with pulmonary arterial hypertension ...

Yutrepia is an inhaled dry powder formulation of treprostinil approved in the U.S. to improve exercise capacity in PAH and PH ...

Liquidia broke out earlier, but has fallen back below the prior 16.81 entry from a consolidation. If a stock you're tracking clears a buy point then falls 7% or more below the ori ...

Detailed price information for Oruka Therapeutics Inc (ORKA-Q) from The Globe and Mail including charting and trades.

Participants treated with atacicept for immunoglobulin A nephropathy (IgAN) achieved a 46% reduction from baseline in ...

Liquidia shares climbed 7.5% after disclosing that it is scheduled to make its first commercial shipment of Yutrepia inhalation powder, days after Food and Drug Administration approval. Shares were ...

Shares of Liquidia Technologies Inc (NASDAQ: LQDA) were up 9.6% following the announcement that the company is scheduled to make its first commercial shipment of YUTREPIA™ (treprostinil) inhalation ...

YUTREPIA now available to be prescribed to patients via specialty pharmaciesFDA approved YUTREPIA on May 23, 2025Court denies United Therapeutics’ request for preliminary injunction and a temporary ...

Liquidia Technologies Inc (NASDAQ:LQDA) saw its shares rise nearly 10% following news that it will begin its initial ...